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Monoisoamyl meso-2,3-dimercaptosuccinate (Mi-ADMS) was found to be superior to meso-2,3-dimercaptosuccinic acid (DMSA) in decreasing the
body burden of 203Hg in rats under conditions of early treatment. In this experiment Mi-ADMS was used as late treatment for mercury removal.
Albino rats aged 6 weeks and 7-day-old sucklings received a single intraperitoneal injection of 23Hg (as nitrate). Two weeks later they were treated
with DMSA or Mi-ADMS (0.25 mmole/kg bw) on two consecutive days. The radioactivity in the carcass (whole body after removal of the gastroin-
testinal tract), liver, kidneys and brain was determined by solid crystal gamma scintillation counting six days after chelation therapy administration (3
weeks after 203Hg application). Both chelators reduced the body burden of mercury compared to controls. The effect of Mi-ADMS was superior to
DMSA treatment in older rats for decreasing carcass and kidney retention, and in suckling rats for decreasing carcass, liver, and kidney retention.
They were equally effective in decreasing brain retention in older rats and had no effect on brain retention in sucklings. The efficiency of Mi-ADMS
in reducing the body burden of mercury was generally higher than the efficiency of the DMSA treatment. Therefore, Mi-ADMS deserves further
attention as a late treatment for mercury removal. - Environ Health Perspect 102(Suppl 3):309-31 1 (1994).
Key words: monoisoamyl meso-2,3-dimercaptosuccinate, delayed parenteral treatment; 203Hg retention, rats
Introduction
Chelation therapy, which decreases the
body burden of metals some time after
metal entry into the body, is ofgreat interest
for practical reasons. The efficiency of
chelating agents is known to depend on the
time delay between metal intoxication and
administration of the chelating agent. The
best therapeutic results are usually obtained
byearly chelation administration (1).
We have recently shown that treatment
with monoalkyl esters of meso-2,3-dimer-
captosuccinic acid (Mi-ADMS)is superior
to treatment with dimercaptosuccinic acid
(DMSA) in decreasing mercury retention
in rats (2). The efficiency increased with
the number of carbon atoms in the alkyl
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group of the DMSA monoester, and the
best results were obtained with Mi-ADMS.
Since treatment with DMSA is an accepted
therapeutic means for reducing the body
burden of mercury (3,4), the newer and
more efficient monoesters-especially Mi-
ADMS-deserve further attention.
Our previous results were obtained
with early (immediate) treatment with
DMSA and its monoesters after intraperi-
toneal administration of 203Hg in rats (2).
In our present experiment, DMSA and Mi-
ADMS were administered two weeks after
203 . . . Hg administration. The experiments
were performed on suckling and older rats;
exposure to mercury in the youngest age
group might be of special concern due to
higher retention and higher toxicity of
mercury at this period ofdevelopment (5).
Our results show that treatment with Mi-
ADMS is superior to DMSA in reducing
mercury body burden in both age groups
ofrats.
Materials and Methods
The experiment was performed on two age
groups of albino Wistar-derived rats from
the Institute's breeding farm in Zagreb,
Croatia. At the beginning of the experi-
ment, the animals were 6 weeks (females,
average weight 130 g) and 7-day old (suck-
lings of both sexes, average weight 12 g).
Suckling rats were kept with their mothers
in clear plastic (polycarbonate) individual
cages, in litters of six per dam (reduced to
this number at birth) till weaning at the age
of3 weeks. The numbers of6-week and 7-
day-old animals were 29 and 42, respec-
tively. Each age group was devided into
three subgroups (control, DMSA, and Mi-
ADMS). Older rats were kept in groups of
9 to 10 in proper polycarbonate cages dur-
ing the experiment.
Each animal received a single intraperi-
toneal injection of 203Hg as nitrate (New
England Nuclear, Boston, MA); specific
activity 21 GBq/g - 0.56 Ci/g). Older rats
received 92.5 kBq (2.5 pCi) in a volume of
0.5 ml, and sucklings 55.5 kBq (1.5 pCi)
in a volume of0.03 ml.
Two weeks later, chelation therapy
with DMSA or Mi-ADMS began. Both
chelators were stored under nitrogen (to
avoid oxidation), and solutions for injec-
tion were prepared immediately prior to
application. Chelators were dissolved in
aqueous 5% NaHCO3 and were adminis-
tered intraperitoneally at a dose of 0.25
mmole/kg bw in a volume of 0.5 ml in
older, and 0.2 ml in younger rats on two
consecutive days, i.e., on days 14 and 15
after 203Hg administration.
Environmental Health Perspectives 309KOSTIAL ETAL.
Table 1. Effect of late chelation therapy on 2BHg retention in rats.
Control, DMSA, Reduction to Mi-ADMS, Reduction to
% dose % dose control, % % dose control, %
6-week-old rats
(9) (10) (10)
Carcass 34.7 ± 0.81 27.4 ± 0.51 21 19.6 ± 1.01 43
Liver 0.572 ± 0.062 0.499 ± 0.059 13 0.388 ± 0.042 32
Kidney 32.8 ± 1.08 25.9 ± 0.52 21 17.8 ± 0.89 46
Brain 0.032 ±0.004 0.023 ± 0.001 27 0.024 ± 0.001 25
7-day-old rats
(14) (14) (14)
Carcass 48.6 ± 1.37 39.0 1.14 20 21.3 0.58 56
Liver 7.51 ±0.32 5.53 0.52 26 3.49 0.17 54
Kidney 28.9 ± 0.96 20.9± 0.89 28 5.97 +0.15 79
Brain 0.512 ± 0.003 0.506 0.017 1 0.471 0.012 8
Results are expressed as arithmetic mean + SEM (number of animals in parentheses). DMSA and Mi-ADMS were
administered intraeritoneally (0.25 mmole/kg) as delayed treatments on days 14 and 15 after a single intraperitoneal
adminstration of Hg.
In each litter at least one rat was used as
control, and two experimental animals
received Mi-ADMS or DMSA treatment.
After each treatment the suckling rats were
returned to the dams.
At the end ofthe experiment, i.e., three
weeks after 203Hg administration, rats were
sacrificed under ether anesthesia by cardiac
exsanguination. The carcass (whole body
after removal of the total gastrointestinal
tract), liver, both kidneys, and brain were
dissected for radioactivity determination.
The radioactivity of the carcass was mea-
sured in a twin crystal whole body scin-
tillation counter (Tobor, Nuclear Chicago,
Des Plains, IL), and the radioactivity in the
organs (liver, kidneys, brain) was measured
in an automatic well-type gamma scintilla-
tion counter (Nuclear, Des Plains, IL). The
results were corrected for radioactive decay
and the geometry ofthe samples.
The results wereexpressed as a percentage
of the radioactive dose, and data are pre-
sented as the arithmetic mean ± SEM. The
results of the treatment were expressed as
percentage reduction to control for 203Hg
retention. Differences between the groups
were evaluated by the two-tailed Student's
t-test and by one way analysis of variance
followed by Duncan's multiple range test
analysis.
Results
In older rats DMSA caused a significant
reduction in carcass, kidney, and brain
retention (percent reduction ofcontrol was
21, 21, and 27, respectively), and had
lower effect on liver retention (Table 1). In
younger rats treatment with DMSA
showed a similar efficiency as in older rats,
in reducing carcass and kidney retention
(20 and 28%, respectively), but caused also a
decrease in liver retention (26%). In these rats
DMSAwaswithout effect on brain retention.
Treatment with Mi-ADMS in older
rats caused a significant reduction in all
body compartments (43% in carcass, 32%
in liver, 46% in kidneys, and 25% in
brain). In younger rats the treatment was
even more efficient in reducing carcass
(56%), liver (54%), and kidney retention
(79%) than in older rats, but was without
effect on brain retention (Table 1). The
efficiency of Mi-ADMS treatment was
therefore generally higher than the effi-
ciency ofDMSA therapy.
The statistical analysis ofthese results is
presented in Table 2, showing the compar-
ative efficiency ofboth treatments. In older
rats Mi-ADMS was superior to DMSA in
decreasing carcass and kidney retention,
and in younger rats in decreasing carcass,
liver, and kidney retention. The lack of
efficiency in reducing brain retention was
similar for both chelators.
Discussion
It has been known that DMSA can be used
as late treatment for mercury removal, but
it is a new and interesting finding that its
monoester Mi-ADMS is superior to DMSA
for this purpose. The reduction in the body
burden ofmercury by Mi-ADMS adminis-
tration was much higher than by DMSA
treatment. An exception is the brain, where
no differences between the efficiency ofthe
two chelators were observed in older rats,
and no effect was obtained in sucklings by
either chelator. This indicates that mercury
incorporated into the brain during the
suckling period is difficult to remove by
late administration of chelators, even with
Mi-ADMS, which was shown to be far
superior to DMSA in reducing brain reten-
tion ofmercury in suckling rats under con-
ditions ofearly treatment (6).
The efficiency of DMSA in decreasing
the body burden in the carcass, liver, and
kidney was similar for both age groups of
rats while for Mi-ADMS the efficiency of
the treatment was even higher in younger
than in older rats. Most mercury chelators
were found previously to be less efficient in
enhancing metal elimination in the young
as compared to older animals (7). In expla-
nation of these results, the immaturity of
the excretory system and differences in
metal-ligand binding were mentioned.
However, these arguments cannot be used
to interpret our present results, since chela-
tors were administered at the age of three
weeks when-according to toxicokinetic
data-absorption, distribution, and elimi-
nation of most metals are similar to those
in older age groups ofrats (8). The higher
efficiency of Mi-ADMS in inducing a
decrease in the body burden ofmercury in
the young remains to be explained.
In conclusion, Mi-ADMS is not only
superior to DMSA as an agent to decrease
the body burden of mercury under condi-
tions ofimmediate parenteral treatment, as
found earlier, but also under conditions of
late parenteral administration some time
after mercury incorporation. In other
words, Mi-ADMS is more suitable for
removal of mercury than DMSA, which is
commonly used in the current therapy of
mercurial intoxication.
Furthermore, Mi-ADMS was also
found to be superior to DMSA in mobilizing
"aged" cadmium deposits in mice (9). This
indicates that further experiments with Mi-
ADMS arejustified, since this chelator might
be the agent of choice in the treatment of
both mercury and cadmium intoxication.
Table 2. Duncan's multiple-range testanalysis of results
from Table 1.
DMSAC/VK/B Mi-ADMSC/L/K/B
6-week-old rats
Control +/-/+/+ +/+1+1+
DMSA +1-1+
7-day-old rats
Control +/+/+/- +1+1+1-
DMSA +/+/+/-
A significant difference with p<0.05 is indicated by +"
and a difference which is not significant by "-". The sig-
nificances are listed for each pairwise comparison in
order: Carcass/Liver/Kidneys/Brain.
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